Hepatitis B News and Research

Latest Hepatitis B News and Research

Saint Luke's liver transplantation program receives CMS certification

The liver transplantation program at Saint Luke's Hospital of Kansas City has received certification by the Centers for Medicare and Medicaid. The certification is an important step in enhancing the hospital's ability to care for Medicare-covered patients suffering from end-stage liver disease, and attract other insurers who base their coverage on the CMS certification.

2 Oct 2013

Researchers develop renal risk index to predict post-transplant end-stage renal disease

End-stage renal disease is one of the major public health problems among solid organ transplant recipients that is associated with death after transplant and high cost of care.

2 Oct 2013

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

New data from Boehringer Ingelheim's hepatitis C virus clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Canada should begin screening 'Baby Boomers' for the hepatitis C virus infection, since this age group is likely the largest group to have the illness, and most don't know they have it, say a group of liver specialists in the Toronto Western Hospital Francis Family Liver Clinic. Unlike many other chronic viral infections, early treatment makes hepatitis C curable.

1 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

New hepatitis virus reported by scientists was a false alarm

The report by scientists of a new hepatitis virus earlier this year was a false alarm, according to UC San Francisco researchers who correctly identified the virus as a contaminant present in a type of glassware used in many research labs.

27 Sep 2013

Johns Hopkins establishes center to study ELSI of applying genomics to infectious disease treatment

The National Human Genome Research Institute has selected the Johns Hopkins Berman Institute of Bioethics to establish a "Center of Excellence" to study the ethical, legal and social implications of genomic research.

19 Sep 2013

Researchers find that people affected by cold sores have mutation in gene

Why some people are troubled by cold sores while others are not has finally been explained by scientists. Cold sores affect around one in five people but, until now, no one has been sure why some are more prone to the virus that causes them.

17 Sep 2013

Study: Higher rates of acute hepatitis C virus clearance are seen in women

A study of patients infected with acute hepatitis C virus (HCV) infection found that women had higher rates of spontaneous viral clearance—undetectable levels of the virus without initiating drug therapy.

13 Sep 2013

T-rays are ideal for detecting early signs of melanoma

The technology that peeks underneath clothing at airport security screening check points has great potential for looking underneath human skin to diagnose cancer at its earliest and most treatable stages, a scientist said here today.

12 Sep 2013

Phobias, anxiety are typical reasons why many decline to donate blood

As few as 3 percent of Americans eligible to donate blood do, and fear and anxiety are common reasons why many decline to give. U.S. hospitals are always in need of new donors; at Mayo Clinic, that need is heightened by concern about iron deficiency in frequent givers.

11 Sep 2013

Combination drug does not improve survival in patients with severe alcoholic hepatitis

Four weeks of treatment with a combination of the drug pentoxifylline and the corticosteroid prednisolone did not improve 6-month survival compared with prednisolone alone in 270 patients with severe alcoholic hepatitis, according to a study in the September 11 issue of JAMA.

11 Sep 2013

Interferon-alpha 2b and ribavirin treatment may be effective for MERS-CoV infection

Treatment with two common drugs reduced viral replication and lung damage when given to monkeys infected with the virus that causes Middle East Respiratory Syndrome. The condition is deadly pneumonia that has killed more than 100 people, primarily in the Middle East.

10 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Boehringer Ingelheim today announced the completion of patient enrolment for a Phase IIa clinical trial investigating a new interferon-free, all-oral, direct-acting antiviral combination treatment for patients with genotype-1a chronic hepatitis C virus infection.

10 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche and Inovio Pharmaceuticals, Inc. announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

10 Sep 2013

Combination of 2 antiviral drugs improves outcome in monkey model of MERS-CoV infection

National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

10 Sep 2013

Hepatitis B News and Research

Latest Hepatitis B News and Research

Saint Luke's liver transplantation program receives CMS certification

Researchers develop renal risk index to predict post-transplant end-stage renal disease

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

Merck & Co. Axes 8,500 In R&D Restructuring

Merck & Co. Axes 8,500 In R&D Restructuring

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

New hepatitis virus reported by scientists was a false alarm

Johns Hopkins establishes center to study ELSI of applying genomics to infectious disease treatment

Researchers find that people affected by cold sores have mutation in gene

Study: Higher rates of acute hepatitis C virus clearance are seen in women

T-rays are ideal for detecting early signs of melanoma

Phobias, anxiety are typical reasons why many decline to donate blood

Combination drug does not improve survival in patients with severe alcoholic hepatitis

Interferon-alpha 2b and ribavirin treatment may be effective for MERS-CoV infection

Roche Signs Up To $422.5M Collaboration With Inovio

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Combination of 2 antiviral drugs improves outcome in monkey model of MERS-CoV infection

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Hepatitis B News and Research

Latest Hepatitis B News and Research

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in